Abstract
Background The ongoing outbreak of the 2019 novel coronavirus (2019-nCoV) in China has led to the declaration of Public Health Emergency of International Concern by the World Health Organization.
Methods All 2019-nCoV infected patients reported to Chinese Center for Disease Control and Prevention up to 26 January 2020 were included for analysis. Disease and death incidence were compared between demographic groups and baseline conditions. Case fatality rates (CFRs) and the basic reproductive number R0 was estimated with a transmission model.
Results As of 26 January 2020, a total of 8866 patients including 4021 (45.35%) laboratory confirmed patients were reported from 30 provinces. Nearly half of the patients were aged 50 years or older (47.7%). There was a clear gender difference in incidence with 0.31 (male) vs. 0.27 (female) per 100,000 people (P<0.001). The median incubation period was 4.75 (interquartile range: 3.0-7.2) days. About 25.5%, 69.9% and 4.5% patients were diagnosed with severe pneumonia, mild pneumonia, and non-pneumonia, respectively. The overall CFR was estimated be 3.06% (95% CI 2.02-4.59%), but male patients, ≥60 years old, baseline diagnosis of severe pneumonia and delay in diagnosis were associated with substantially elevated CFR. The R0 was estimated to be 3.77 (95% CI 3.51-4.05), ranging 2.23-4.82 in sensitivity analyses varying the incubation and infectious periods.
Conclusions Compared with SARS-CoV, 2019-nCoV had comparable transmissibility and lower CFR. Our findings based on individual-level surveillance data emphasize the importance of early detection of elderly patients, particularly males, before symptoms progress to severe pneumonia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was financially supported by grants from the China Mega-Project on Infectious Disease Prevention (No. 2018ZX10713001, 2018ZX10713002, 2017ZX10103004 and 2018ZX10101003-002), the National Natural Science Funds (No. 81825019), and the U.S. National Institute of Health (R01 AI139761 and R01 AI116770).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Request for individual case data should be directed to Chinese Center for Disease Control and Prevention. Summary data used for tables and figures in this manuscript can be requested by emailing the corresponding authors.
